Functional TFEB activation characterizes multiple models of renal cystic disease and loss of polycystin-1

Jonathan M Shillingford1, James A Shayman1

  • 1Department of Internal Medicine, University of Michigan Medical School, University of Michigan, Ann Arbor, Michigan, United States.

Insights

Transcription factor EB (TFEB) activation is a key feature in polycystic kidney disease, driving cyst growth. This finding in multiple models suggests a new therapeutic target for renal cystic diseases.

Area of Science:

  • Nephrology
  • Cell Biology
  • Molecular Biology

Background:

  • Polycystic kidney disease (PKD) involves abnormal renal epithelial cell growth and differentiation.
  • Transcription factor EB (TFEB) regulates lysosome biogenesis and cellular waste removal.
  • The role of TFEB in PKD pathogenesis was previously unclear.

Purpose of the Study:

  • To investigate the role of TFEB in the development and progression of renal cystic diseases.
  • To determine if TFEB activation is a common feature across different PKD models.
  • To explore TFEB's functional impact on cyst formation and growth.

Main Methods:

  • Studied TFEB nuclear translocation and function in murine models of PKD (folliculin, polycystin-1 knockouts).
  • Utilized mouse embryonic fibroblasts lacking Pkd1 and 3D Madin-Darby canine kidney cell cultures.
  • Examined TFEB-dependent gene expression, lysosomal activity, and autophagy in cystic epithelia and fibroblasts.
  • Assessed TFEB activation in human autosomal dominant polycystic kidney disease (ADPKD) tissue.

Main Results:

  • Nuclear TFEB translocation was consistently observed in cystic epithelia across all PKD models and human ADPKD samples.
  • TFEB activation correlated with increased expression of TFEB-dependent genes (e.g., cathepsin B).
  • Pkd1-deficient cells showed enhanced lysosomal biogenesis, autophagy, and TFEB activity.
  • TFEB agonist (Compound C1) significantly increased cyst growth in cell cultures.

Conclusions:

  • Noncanonical TFEB activation is a hallmark of cystic epithelia in diverse renal cystic disease models, including Pkd1 loss.
  • Nuclear TFEB translocation is functionally active, contributing to cystogenesis and growth.
  • TFEB represents a potential therapeutic target and a novel paradigm for treating cystic kidney diseases.